BCP has been shown to activate PPARγ, the main target of clinically used insulin sensitizers, thiazolidinedione drugs which are pharmacologically known as PPARγ agonists and used in IR and T2DM as insulin sensitizers [58]. This evidence concerns the gene OPN1SW and type 2 diabetes mellitus.